When the inspection ends, the clock starts.
Veritas Quality Consultants helps pharmaceutical and medical device companies turn a Form 483 into a defensible, science-led response — root cause done right, CAPAs that hold, and a submission built to the FDA's expectations.
A 483 is an observation — not a verdict. What you do next decides the outcome.
The inspectional observations listed on a Form 483 are not the FDA's final conclusions. A complete, timely, evidence-backed response is the single best lever you have to keep the matter from escalating.
Business days to respond
Respond within 15 business days and your reply is reviewed alongside the inspection. Miss it, and the agency may proceed without your input.
Repeat observations escalate risk
A repeated observation signals that prior corrections failed to hold — a significant red flag that increases the likelihood of a Warning Letter or further action.
Product already on the market
Observations can implicate distributed product. A patient- and product-focused risk assessment is now an expected element of a credible response.
Remediation that satisfies the reviewer and survives the next inspection.
We work as an extension of your quality unit — from the first triage through the final submission and its effectiveness checks.
Root cause investigation
Scientifically sound investigations that find the underlying system weakness — not the nearest symptom. The cornerstone of any response the FDA will accept.
Our value propositionCAPA program development
Containment, systemic correction, and a real effectiveness evaluation — CAPAs designed to prevent recurrence, not just schedule retraining.
Sustainable by designResponse drafting
A comprehensive, well-structured submission built to current FDA format: executive summary table, investigation reports, contextualized evidence.
FDA-format readyPatient & product risk assessment
Determine whether an observation affects distributed product, and document a defensible, patient-focused risk position the agency expects to see.
Market-impact analysisQuality in a service or product is not what you put into it. It is what the client or customer gets out of it.Peter Drucker
Truth, documented and defensible.
We don't write reassurances. We build investigations that stand up to scrutiny and corrective actions that close the gap for good — working on the shop floor alongside your team.
Science over narrative
Every conclusion is traceable to objective evidence — the standard an FDA reviewer applies.
Built for the deadline
We plan around the 15-day window and a clear interim communication strategy when full remediation needs longer.
Systems, not band-aids
We target the quality-system weakness so the same observation never returns on the next inspection.
"It is not enough to say we'll fix it. The investigation must identify the underlying system weakness — and prove the fix works."
Just received a Form 483?
Send us the observations. We'll help you triage scope, map your deadline, and outline a response strategy — fast.
Request a consultationWe build and defend GxP quality systems.
We assess and optimize your quality-system workflows to ensure regulatory adherence and stronger quality performance — in an environment built on respect, trust, and a common goal. Our consultants bring deep experience across all GxP (GMP, GLP, GCP) systems.
Root cause analysis
Scientifically defensible investigations — structured techniques, objective evidence, and a clear line from finding to underlying cause. Where most responses fail, and where we add the most value.
Consulting on investigationsDeviation & CAPA management
Robust, sustainable CAPA systems: immediate containment, systemic corrections that prevent recurrence, and a defined effectiveness evaluation to verify the measures work.
Designing CAPA systems483 response & structure
A comprehensive, well-structured response built to current FDA format expectations — executive summary table, investigation report per observation, contextualized supporting evidence.
Drafting the responseProduct impact & risk assessment
A patient- and product-focused risk assessment to determine whether an observation affects product already on the market — and to document a defensible position.
Market-impact analysisThe full range of GMP quality support.
We specialize in helping you develop and enhance your GMP Quality System to meet your regulatory requirements — including GMP compliance training, equipment and system qualification, metrics development, SOP preparation, deviation and CAPA management, and vendor qualification.
QA services
- FDA 483 response support
- Quality Policy Manual development
- Data integrity assessment for submission & clinical trial batches
Auditing services
- Quality system evaluation
- Mock FDA audits
- GxP audits & assessments
- Compliance gap assessments
- Batch review
Quality control services
- Effective investigations & CAPAs
- GMP compliance
- Method transfers
Hands-on depth across the quality system.
Our backgrounds and industry experience are well suited to evaluate, improve, or build your GxP quality systems. Familiarity with current systems and technologies lets us find effective, durable solutions.
Risk management
Review against ICH Q9 and ICH Q3D, and for medical device, 21 CFR 820 and ISO 14971. Strategic support for risk initiatives, FMEA and hazard analysis, and a working risk register.
Data integrity
Forensic data-integrity assessments that identify gaps across quality and manufacturing systems, with documentation review of batch records and metadata under 21 CFR parts 210, 211 & 212.
Process improvement
Lean Six Sigma training, Kaizen events, and benchmarking against industry practice — analyze, optimize, and sustain processes through data-driven decisions and relevant metrics.
Vendor auditing
Focused, systems, and due-diligence audits of suppliers and contractors that impact GMP product integrity — from contract manufacturers to API suppliers — plus reduced-testing qualification.
Systems validation
Review of quality systems for software and computerized elements — creation, modification, maintenance, archival, and transmission of data — designed to preclude data errors.
Training
Employee qualification, continuing GMP training, and external-provider training. Modular courses on cGMPs and good documentation, inspection readiness, and conducting investigations.
When you need us
You require support for an impending client or regulatory inspection.
Veritas Quality Consultants can mobilize quickly. A typical engagement includes:
- A pre-inspection GMP audit by one or more of our internationally experienced auditors (typically 1–3 days).
- An audit report outlining deficiencies with a proposed remedial action plan to ensure GMP compliance.
- On-site and/or remote support to complete the action plan.
- Support for equipment qualification or calibration, where applicable.
- On-site support during the client or regulatory inspection.
Not sure which observations carry the most risk?
That's our first conversation. We'll help you separate documentation findings from systemic ones and prioritize accordingly.
Talk to VeritasHands-on direction, from design to continuous improvement.
Our consultants provide hands-on direction in the design, implementation, and continuous improvement of Quality Management Systems — assuring product safety, strength, identity, purity, and quality, and building systems that prevent, detect, and correct deficiencies in the normal process.
We measure actual system performance against requirements.
We ensure systems are in place to monitor performance and to escalate, identify, and implement corrective actions as appropriate — across every element of your operation.
Three phases, one defensible submission.
For an inspectional finding, our path runs from the first read of the form to a response the FDA can accept — and an operation prepared for the next inspection.
Immediate assessment & triage
We capture the key facts the moment the form is in hand, then size the urgency and scope of the work.
Calculate the deadline
Count 15 business days from Day 0, excluding weekends and federal holidays — and target a draft 2–3 days early for final preparation.
Review compliance history
Pull prior 483s, responses, and Warning Letters. A repeated observation is a significant red flag that raises the stakes.
Parse the observations
Extract each observation for analysis, keeping in mind these are inspectional observations — not final conclusions.
In-depth observation analysis
For every observation, we analyze nature and severity, then open the formal processes the agency expects to see underway.
Identify the core issue
Pinpoint the specific violation — documentation, quality systems, or facility and equipment — and address the facts as noted.
Initiate CAPAs
Open a formal CAPA per observation immediately, documenting investigation plans so the response shows action already in motion.
Assess product impact
Run a patient- and product-focused risk assessment to determine whether distributed product is affected.
Define the core response strategy
We assemble the components of a response that holds — anchored by a thorough root cause analysis and structured to current FDA guidance.
Root cause investigation
A scientifically sound investigation that identifies the underlying system weakness — the cornerstone of acceptability.
CAPA plan
Immediate containment, systemic corrections that prevent recurrence, and an effectiveness evaluation to verify the fix works.
Communication plan
Interim updates and, where needed, a commitment letter with a realistic timeline for full remediation.
Structuring the response
Current FDA draft guidance points to a specific format. A strong submission includes:
We work on the shop floor.
Our hands-on approach and familiarity with current systems and technologies let us find effective solutions to real Quality and Regulatory compliance issues. Working alongside our clients on the floor is one of the things that sets Veritas apart.
"Quality is never an accident; it is always the result of high intention, sincere effort, intelligent direction and skillful execution."
Seasoned practitioners, collaborative by default.
Our diverse team brings extensive knowledge and technical experience to help you overcome your regulatory challenges. We treat each project as a collaborative endeavor with solutions designed specifically for our clients — giving you a sense of confidence and helping you achieve commercial success.
Claude Chingwe
Claude has over 31 years of pharmaceutical experience, including 16 years in quality management, at Schering-Plough Corporation, Merck, and Whitehouse Analytical Laboratory — where he oversaw personnel involved in pharmaceutical packaging component, raw materials, in-process, and finished-product testing and analysis.
He was actively involved in the Quality System upgrades and enhancements that led to Schering-Plough's successful completion of all FDA-mandated work plans required to lift the FDA's Consent Decree.
He works in close collaboration with Lachman Consultants (12 years) and 5Ws GxPertise (7 years) — partnerships that extend Veritas's reach with deep, complementary regulatory and compliance expertise.
Stevens Institute of Technology
University of Zambia
Rutgers University
Certified practitioner
Work directly with our principals.
Every engagement is led by senior practitioners with hands-on industry experience.
Request a consultationLet's map your response.
Tell us where you are in the process. If a 483 is already in hand, include the issue date and we'll start with your deadline.
- Office
- 1691 Charlion Downs Lane
Apex, NC 27502 - veritasqualityconsultants@gmail.com
- Phone
- (732) 500-6753
- Web
- www.veritasqualityconsultants.com
- Principal
- Claude Chingwe, President